PAVM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PAVmed Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show a bearish trend, the options data reflects low activity, and the financial performance is weak despite revenue growth. Analysts have lowered the price target significantly, and there are no strong positive catalysts or recent influential trades to support a buy decision.
The stock is showing bearish signals with the MACD histogram below 0 and negatively contracting, RSI in the neutral zone at 43.201, and moving averages indicating a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 9.347, with support at 9.078 and resistance at 9.615.
Revenue increased significantly by 420% YoY in Q4 2025, indicating potential growth in the company's operations.
Net income dropped significantly by -236.11% YoY, and gross margin declined by -83.30% YoY. Analysts have lowered the price target from $60 to $16 due to equity dilution concerns. Additionally, the recent capital raise by Lucid Diagnostics (a related entity) at a low price per share may indicate financial strain.
In Q4 2025, revenue increased to $52,000 (up 420% YoY), but net income dropped to -$1,832,000 (down -236.11% YoY). EPS improved to -2.05 (up 469.44% YoY), but gross margin dropped significantly to -63.46% (down -83.30% YoY).
Maxim lowered the price target from $60 to $16 and maintained a Buy rating, reflecting concerns about equity dilution and a higher expected share count.
